Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix™) (GSK-580299) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) (GSK-208109) in Healthy Female Adolescents Aged 9-14 Years

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT02082639

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:35:52.589180+00:00

Published At

2015-07-20T00:00:00+00:00

Record Updated At

2015-07-20

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Infections, Papillomavirus"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2015-07-20"

protocolSection.identificationModule.nctId

"NCT02082639"

protocolSection.identificationModule.officialTitle

"Immunogenicity and Safety Study of GSK Biologicals\u0027 Human Papillomavirus (HPV) Vaccine (Cervarix\u2122) (GSK-580299) When Co-administered With GSK Biologicals\u0027 Hepatitis A Vaccine (Havrix\u00ae) (GSK-208109) in Healthy Female Adolescents Aged 9-14 Years"

protocolSection.statusModule.overallStatus

"WITHDRAWN"

protocolSection.designModule.phases

["PHASE3"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Infections, Papillomavirus (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.